Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics

Bio-Rad Laboratories, Inc. (BIO)

Today's Latest Price: $467.49 USD

0.85 (-0.18%)

Updated Jul 8 4:10pm

Add BIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BIO Stock Summary

  • BIO has a higher market value than 88.63% of US stocks; more precisely, its current market capitalization is $13,800,032,088.
  • Bio-Rad Laboratories Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
  • Over the past twelve months, BIO has reported earnings growth of 156.83%, putting it ahead of 92.4% of US stocks in our set.
  • Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are XYL, SNN, RDY, CERN, and TFX.
  • Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to
BIO Daily Price Range
BIO 52-Week Price Range

BIO Stock Price Chart Technical Analysis Charts

BIO Price/Volume Stats

Current price $467.49 52-week high $497.42
Prev. close $468.34 52-week low $303.82
Day low $464.01 Volume 170,266
Day high $473.25 Avg. volume 258,842
50-day MA $457.72 Dividend yield N/A
200-day MA $387.54 Market Cap 13.86B

Bio-Rad Laboratories, Inc. (BIO) Company Bio

Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.

BIO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Bio-Rad Laboratories Inc. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 58.5%. As for the metrics that stood out in our discounted cash flow analysis of Bio-Rad Laboratories Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 88.91 -- which is good for besting 94.02% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately just 13.08% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 48.71% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

NUVA, LCI, PKI, GTS, and HOLX can be thought of as valuation peers to BIO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

BIO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BIO Latest Social Stream

Loading social stream, please wait...

View Full BIO Social Stream

Latest BIO News From Around the Web

Below are the latest news stories about Bio-Rad Laboratories Inc that investors may wish to consider to help them evaluate BIO as an investment opportunity.

3 Health Care Companies That Beat the Market in the 1st Half of the Year

GuruFocus screener identifies top performers amid coronavirus pandemic Continue reading...

Yahoo | June 30, 2020

Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.

Yahoo | June 30, 2020

Top Health Care Stocks for July 2020

Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 6.8% compared to the S&P 500's total return of 5.5% over the past 12 months. The market performance numbers and the statistics in the tables in this story are as of June 24.

Yahoo | June 25, 2020

T. Rowe Price and Align Technology Show High Profit, Low Debt

High profits are a sign of a competitive advantage. The trick is to find a durable advantage Continue reading...

Yahoo | June 15, 2020

S&P Dow Jones Indices Announces Tyler Technologies, Bio-Rad Laboratories and Teledyne Technologies Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

S&P; Dow Jones Indices will make the following index adjustments to the S&P; 500, S&P; MidCap 400 and S&P; SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, June 22 to coincide with the June quarterly rebalance.

Yahoo | June 12, 2020

Read More 'BIO' Stories Here

BIO Price Returns

1-mo 2.40%
3-mo 18.91%
6-mo 21.89%
1-year 53.25%
3-year 104.14%
5-year 215.94%
YTD 26.34%
2019 59.34%
2018 -2.70%
2017 30.94%
2016 31.46%
2015 15.01%

Continue Researching BIO

Want to see what other sources are saying about Bio-Rad Laboratories Inc's financials and stock price? Try the links below:

Bio-Rad Laboratories Inc (BIO) Stock Price | Nasdaq
Bio-Rad Laboratories Inc (BIO) Stock Quote, History and News - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.3998 seconds.